N L Bartlett

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Hodgkin's disease: prognostic factors and short-course regimens
    N L Bartlett
    Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8056, St Louis, MO 63110, USA
    Curr Oncol Rep 2:163-71. 2000
  2. doi request reprint Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551
    Nancy L Bartlett
    Washington University School of Medicine, 600 South Euclid, Box 8056, St Louis, MO, 63110, USA
    Cancer Chemother Pharmacol 63:793-8. 2009
  3. doi request reprint Modern treatment of Hodgkin lymphoma
    Nancy L Bartlett
    Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri 63144, USA
    Curr Opin Hematol 15:408-14. 2008
  4. ncbi request reprint Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
    N L Bartlett
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Ann Oncol 18:1071-9. 2007
  5. ncbi request reprint Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854
    N L Bartlett
    Washington University School of Medicine, St. Louis, Missouri, USA
    Cancer 92:207-17. 2001
  6. ncbi request reprint Cyclin D1 as an aid in the diagnosis of mantle cell lymphoma in skin biopsies: a case report
    B R Moody
    Division of Dermatology, Washington University School of Medicine, St. Louis, Missouri, USA
    Am J Dermatopathol 23:470-6. 2001
  7. ncbi request reprint Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906
    Sonali M Smith
    University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 47:1511-7. 2006
  8. ncbi request reprint Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 48:1313-9. 2007
  9. ncbi request reprint Therapy of relapsed Hodgkin lymphoma
    Amanda F Cashen
    Division of Oncology, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    Blood Rev 21:233-43. 2007
  10. pmc A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
    Nancy L Bartlett
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 111:1848-54. 2008

Research Grants

  1. WUMC-Cancer and Leukemia Group B
    Nancy Bartlett; Fiscal Year: 2007

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Hodgkin's disease: prognostic factors and short-course regimens
    N L Bartlett
    Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8056, St Louis, MO 63110, USA
    Curr Oncol Rep 2:163-71. 2000
    ..Preliminary reports of short-course chemotherapy regimens with and without radiotherapy for all stages of Hodgkin's disease are summarized...
  2. doi request reprint Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551
    Nancy L Bartlett
    Washington University School of Medicine, 600 South Euclid, Box 8056, St Louis, MO, 63110, USA
    Cancer Chemother Pharmacol 63:793-8. 2009
    ..To evaluate the efficacy and toxicity of the topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), in patients with relapsed lymphoma and to correlate 9-AC plasma concentrations with response and toxicity...
  3. doi request reprint Modern treatment of Hodgkin lymphoma
    Nancy L Bartlett
    Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri 63144, USA
    Curr Opin Hematol 15:408-14. 2008
    ....
  4. ncbi request reprint Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
    N L Bartlett
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Ann Oncol 18:1071-9. 2007
    ..Because of high single-agent activity and modest toxicity, we hypothesized the combination of gemcitabine (G), vinorelbine (V), and pegylated liposomal doxorubicin (D) would be an effective salvage therapy for Hodgkin's lymphoma (HL)...
  5. ncbi request reprint Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854
    N L Bartlett
    Washington University School of Medicine, St. Louis, Missouri, USA
    Cancer 92:207-17. 2001
    ..However, response and survival rates of patients who receive dose-escalated CHOPE, even with the addition of G-CSF, appear similar to the rates reported with standard-dose CHOP...
  6. ncbi request reprint Cyclin D1 as an aid in the diagnosis of mantle cell lymphoma in skin biopsies: a case report
    B R Moody
    Division of Dermatology, Washington University School of Medicine, St. Louis, Missouri, USA
    Am J Dermatopathol 23:470-6. 2001
    ....
  7. ncbi request reprint Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906
    Sonali M Smith
    University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 47:1511-7. 2006
    ..The activity in Burkitt's lymphoma should be investigated further...
  8. ncbi request reprint Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 48:1313-9. 2007
    ..Grade 3 - 4 adverse events, primarily thrombocytopenia, occurred in 15 patients. Therefore, although well tolerated, 1.3 mg/m(2) bortezomib administered biweekly has no single agent activity in relapsed/refractory classical HL...
  9. ncbi request reprint Therapy of relapsed Hodgkin lymphoma
    Amanda F Cashen
    Division of Oncology, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    Blood Rev 21:233-43. 2007
    ..New salvage regimens that incorporate gemcitabine, vinorelbine, rituximab, and/or monoclonal antibodies against CD30 are being investigated...
  10. pmc A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
    Nancy L Bartlett
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 111:1848-54. 2008
    ..These results demonstrate that weekly administration of SGN-30 is safe and has modest clinical activity in patients with CD30(+) tumors. This trial is registered at http://www.ClinicalTrials.gov as no. NCT00051597...
  11. doi request reprint High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlati
    Raymond Lai
    Leuk Lymphoma 49:1202-5. 2008
  12. ncbi request reprint Management of advanced stage Hodgkin's lymphoma
    Nancy L Bartlett
    Washington University, Siteman Cancer Center, Division of Medical Oncology 660 South Euclid Street, St Louis, MO 63110, USA
    Cancer Treat Res 131:333-52. 2006
  13. ncbi request reprint 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma
    Kristie A Blum
    The Ohio State University, Division of Hematology and Oncology, Arthur G James Cancer Hospital, Columbus 43210 1240, USA
    Expert Opin Biol Ther 4:1323-31. 2004
    ..Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttrium-ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL...
  14. ncbi request reprint Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial
    Sandra J Horning
    Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA 94304, USA
    J Clin Oncol 20:630-7. 2002
    ..To provide more mature data on the efficacy and complications of a brief, dose-intense chemotherapy regimen plus radiation therapy (RT) to bulky disease sites for locally extensive and advanced-stage Hodgkin's disease...
  15. ncbi request reprint Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:2453-63. 2002
    ....
  16. ncbi request reprint Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
    Gregory A Wiseman
    Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:4336-42. 2002
    ..The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population...
  17. ncbi request reprint Salvage regimens for Hodgkin lymphoma
    Amanda F Cashen
    Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Adv Hematol Oncol 6:517-24. 2008
    ....
  18. ncbi request reprint Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
    Paula M Fracasso
    Alvin J Siteman Cancer Center, St Louis, Missouri, USA
    Cancer 95:2223-9. 2002
    ..We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancies...
  19. ncbi request reprint Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
    Bradley C Ekstrand
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94304, USA
    Blood 101:4285-9. 2003
    ..Further clinical trials are warranted to determine the optimal dosing schedule of rituximab, the potential for combination treatment, and the possible relationship of rituximab treatment to the development of LCL...
  20. ncbi request reprint Interdigitating dendritic reticulum cell tumor of lymph nodes: case report with differential diagnostic considerations
    Lourdes R Ylagan
    Lauren V Ackerman Laboratory of Surgical Pathology, Department of Pathology and Immunology, Barnes Jewish Hospital, Washington University Medical Center, St Louis, Missouri, USA
    Diagn Cytopathol 28:278-81. 2003
    ..This case report is the first to illustrate the FNA cytomorphology of IDRCT and to discuss the cytologic differential diagnosis of this rare tumor type in lymph nodes...
  21. ncbi request reprint Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Biother Radiopharm 18:165-78. 2003
    ..These correlations were not consistent across the total patient population, and therefore, could not be exploited to predict hematologic toxicity...
  22. ncbi request reprint Antibodies for the treatment of diffuse large cell lymphoma
    Kristie A Blum
    Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA
    Semin Oncol 30:448-56. 2003
    ..These agents may be most promising when combined with either chemotherapy or with rituximab. This review will summarize the use of rituximab in the therapy of diffuse large B-cell lymphoma and briefly describe antibodies in development...
  23. pmc High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
    Christian Langer
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:5371-9. 2008
    ..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...
  24. doi request reprint Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B
    Sonali M Smith
    The University of Chicago, Chicago, IL 60637, USA
    Br J Haematol 140:313-9. 2008
    ..Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide...

Research Grants3

  1. WUMC-Cancer and Leukemia Group B
    Nancy Bartlett; Fiscal Year: 2007
    ....